What are the Data on 5α-Reductase Inhibitor Treatment of Benign Prostatic Hyperplasia from Everyday Practice?  François Desgrandchamps  European Urology.

Slides:



Advertisements
Similar presentations
Volume 42, Issue 1, Pages 7-11 (July 2002)
Advertisements

The Impact of Nocturia on Health Status and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) 
Medical Management for BPH: The Role of Combination Therapy
Volume 77, Issue 1, Pages (January 2011)
Pascal Rischmann  European Urology Supplements 
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Volume 43, Issue 5, Pages (May 2003)
Achieving the Total Approach in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) Management  Michael O’Leary  European Urology Supplements 
Management of Acute and Chronic Retention in Men
Combination of Alfuzosin and Sildenafil is Superior to Monotherapy in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction  Steven A. Kaplan,
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?
Rowland Illing  European Urology Supplements 
Volume 64, Issue 3, Pages (September 2013)
Volume 43, Issue 5, Pages (May 2003)
Volume 55, Issue 2, Pages (February 2009)
Volume 46, Issue 4, Pages (October 2004)
Back to the Future: Introduction and Conclusions
Volume 197, Issue 2, Pages S189-S197 (February 2017)
Volume 52, Issue 3, Pages (September 2007)
What is New in Hormone Therapy for Prostate Cancer in 2007?
Rowland Illing  European Urology Supplements 
Marcel J. Steggerda, Henk G. van der Poel, Luc M.F. Moonen 
A Novel Treatment of Premature Ejaculation
Volume 58, Issue 3, Pages (September 2010)
Treatment of Symptomatic Benign Prostatic Hyperplasia: Current and Future Clinical Practice in Europe – What is Really Happening?  Bob Djavan  European.
Volume 61, Issue 3, Pages (March 2012)
Counselling the Prostate Cancer Patient
Volume 68, Issue 4, Pages (October 2015)
Laurent Boccon-Gibod  European Urology Supplements 
Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European.
Richard C. Harkaway  European Urology Supplements 
Tim Schneider  European Urology Supplements 
Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy  Bertrand Tombal, Richard Berges  European Urology.
Transurethral Resection of the Prostate
Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH):
The Importance of Testosterone Control in Prostate Cancer
Antonio Alcaraz, Pierre Teillac  European Urology Supplements 
Jacques Irani  European Urology Supplements 
Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice  Claus Roehrborn  European Urology.
Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH):
Neal Shore  European Urology Supplements 
When to Treat the Prostate, the Bladder, or Both?
Long-Term Hormonal Therapy: Who Would Benefit?
Challenges and Opportunities in Hormone-Resistant Prostate Cancer
Volume 53, Issue 6, Pages (June 2008)
Christian Stief  European Urology Supplements 
Emmanuel Chartier-Kastler, Kate Davidson  European Urology Supplements 
A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study  John Fitzpatrick  European.
Martin Michel, Jean de la Rosette  European Urology Supplements 
How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?  Vincenzo Mirone 
Richard Berges  European Urology Supplements 
Improving Flexibility and Quality of Life for Your Patients: A Must?
The Burden of Stress Urinary Incontinence
Profile of Silodosin European Urology Supplements
New Concepts in Epidemiology of Lower Urinary Tract Symptoms in Men
The Impact of Nocturia on Health Status and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) 
The Benefits of Dual Inhibition of 5α Reductase
C.G Roehrborn, T McNicholas  European Urology Supplements 
Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer  Sten Holmäng  European Urology.
Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma  Jan Roigas  European Urology Supplements  Volume.
Joaquim Bellmunt  European Urology Supplements 
Oncoforum Urology: Prostate Cancer 2008 at a Glance
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Integrating Patient Risk Profiles in the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) in Clinical Practice 
Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas 
Epidemiology and Demographics of Prostatitis
New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer  Noel W. Clarke  European Urology Supplements 
Michael Marberger  European Urology Supplements 
Vassilios Tzortzis, Stavros Gravas, Jean J.M.C.H. de la Rosette 
Presentation transcript:

What are the Data on 5α-Reductase Inhibitor Treatment of Benign Prostatic Hyperplasia from Everyday Practice?  François Desgrandchamps  European Urology Supplements  Volume 6, Issue 6, Pages 460-466 (March 2007) DOI: 10.1016/j.eursup.2007.01.011 Copyright © 2007 Terms and Conditions

Fig. 1 The proportion of patients with mild (International Prostate Symptom Score [IPSS], 0–7), moderate (IPSS, 8–19), and severe (IPSS, ≥20) symptoms at baseline and week 24 in a French open-label study of dutasteride in symptomatic benign prostatic hyperplasia [15]. European Urology Supplements 2007 6, 460-466DOI: (10.1016/j.eursup.2007.01.011) Copyright © 2007 Terms and Conditions

Fig. 2 Comparison of mean International Prostate Symptom Scores from a French open-label study and the phase 3 programme of dutasteride in men with symptomatic benign prostatic hyperplasia [14,15]. European Urology Supplements 2007 6, 460-466DOI: (10.1016/j.eursup.2007.01.011) Copyright © 2007 Terms and Conditions

Fig. 3 Mean change in quasi-American Urological Association Symptom Score over 6 yr of finasteride treatment in men with symptomatic benign prostatic hyperplasia [20]. The first year was double-blind with the subsequent 5 yr open-label. European Urology Supplements 2007 6, 460-466DOI: (10.1016/j.eursup.2007.01.011) Copyright © 2007 Terms and Conditions

Fig. 4 Mean change in American Urological Association Symptom Index scores (A) and Qmax (B) from baseline over 48 mo from the open-label extension study to the phase 3 programme with dutasteride [23]. Line with striped squares=placebo/dutasteride-treated subjects (P/D); line with dotted squares=dutasteride/dutasteride-treated subjects (D/D). For panel A, *p<0.001 between treatment groups; †p<0.001 for differences for both treatment groups from month 24. For panel B, *p<0.001 between treatment groups; ‡p=0.032 between treatment groups; †p=0.042 between treatment groups; ¤p<0.001 versus month 24; §p=0.039 versus month 24; ×p=0.007 versus month 24. European Urology Supplements 2007 6, 460-466DOI: (10.1016/j.eursup.2007.01.011) Copyright © 2007 Terms and Conditions